![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received for publication January 21, 2005.
Revised April 5, 2005.
Accepted for publication April 5, 2005.
Azumolene is an analog of dantrolene, the only approved medicine for treatment of malignant hyperthermia (MH). The pharmacological mechanism of these drugs is to inhibit skeletal muscle sarcoplasmic reticulum (SR)Ca2+ release by modulating the activity of the SR ryanodine receptor (RyR) Ca2+ release channel. To investigate the effects of azumolene on SR Ca2+ channel gating within skeletal muscle fibers, we monitored Ca2+ sparks in permeabilized frog skeletal muscle fibers. Application of 0.0001~10 µM azumolene suppressed the frequency of spontaneous Ca2+ sparks in a dose-dependent manner (EC50=0.25µM, Hill coefficient =1.44), but did not cause systematic dose-dependent effects on the properties of the Ca2+ sparks. These results suggest that azumolene decreases the likelihood of Ca2+ release channel openings that initiate Ca2+ sparks, thereby decreasing spark frequency, but has little effect on aggregate Ca2+ channel open times during a spark. To assess azumolene inhibition of RyRs activated in a manner analogous to those activated during an MH episode, we applied DP4, a synthetic peptide corresponding to a central region of RyR1 (Leu2442 to Pro2477), which mimics an MH modification. Azumolene also decreased Ca2+ spark frequency in a dose dependent manner without altering spark properties in the DP4 MH model. We conclude that azumolene suppresses the opening rate but not the open time of RyR Ca2+ release channels within skeletal fibers.
Key words:
Ca2+ release, Ryanodine receptor, excitation-contraction coupling, malignant hyperthermia, muscle activation, muscle relaxant
This article has been cited by other articles:
|
|
 |
|
  D. Jiang, W. Chen, J. Xiao, R. Wang, H. Kong, P. P. Jones, L. Zhang, B. Fruen, and S. R. W. Chen Reduced Threshold for Luminal Ca2+ Activation of RyR1 Underlies a Causal Mechanism of Porcine Malignant Hyperthermia J. Biol. Chem., July 25, 2008; 283(30): 20813 - 20820. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Cherednichenko, C. W. Ward, W. Feng, E. Cabrales, L. Michaelson, M. Samso, J. R. Lopez, P. D. Allen, and I. N. Pessah Enhanced Excitation-Coupled Calcium Entry in Myotubes Expressing Malignant Hyperthermia Mutation R163C Is Attenuated by Dantrolene Mol. Pharmacol., April 1, 2008; 73(4): 1203 - 1212. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. L. Diaz-Sylvester, M. Porta, and J. A. Copello Halothane modulation of skeletal muscle ryanodine receptors: dependence on Ca2+, Mg2+, and ATP Am J Physiol Cell Physiol, April 1, 2008; 294(4): C1103 - C1112. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. D. Brown, G. G. Rodney, E. Hernandez-Ochoa, C. W. Ward, and M. F. Schneider Ca2+ sparks and T tubule reorganization in dedifferentiating adult mouse skeletal muscle fibers Am J Physiol Cell Physiol, March 1, 2007; 292(3): C1156 - C1166. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Zhao, N. Weisleder, X. Han, Z. Pan, J. Parness, M. Brotto, and J. Ma Azumolene Inhibits a Component of Store-operated Calcium Entry Coupled to the Skeletal Muscle Ryanodine Receptor J. Biol. Chem., November 3, 2006; 281(44): 33477 - 33486. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hollingworth, W. K. Chandler, and S. M. Baylor Effects of Tetracaine on Voltage-activated Calcium Sparks in Frog Intact Skeletal Muscle Fibers J. Gen. Physiol., February 27, 2006; 127(3): 291 - 307. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
